Earlier this month I attended my first Forbes Healthcare Summit, where the stated goal for this year was to “figure out how to create the kind of care we know we deserve.” The event offered a unique gathering of pharmaceutical, health care and biotechnology chief executives engaged in frank discussions
Earlier this month I attended my first Forbes Healthcare Summit, where the stated goal for this year was to “figure out how to create the kind of care we know we deserve.” The event offered a unique gathering of pharmaceutical, health care and biotechnology chief executives engaged in frank discussions
The high cost of pricing myopia When launching a pharmaceutical product, it’s not enough to negotiate the best reimbursable price for each local market. Overall financial performance will depend on successfully managing go-to-market strategies at the global level. That means determining the optimal price and launch sequence for all the
The high cost of pricing myopia When launching a pharmaceutical product, it’s not enough to negotiate the best reimbursable price for each local market. Overall financial performance will depend on successfully managing go-to-market strategies at the global level. That means determining the optimal price and launch sequence for all the
“The most successful life sciences companies will be the ones that can convince their customers – patients, health care professionals, government authorities and health plans – that new treatments are the most effective and provide true value compared with alternatives.” Jamie Powers, DrPH, Principal Consultant and Practice Lead, SAS Health
